Time to review fibrate prescribing?

Drug Ther Bull. 2019 Oct;57(10):154-157. doi: 10.1136/dtb.2018.000060. Epub 2019 Jul 29.

Author

Christopher Nicholas Floyd^{1

2}

Affiliations

¹ Department of Clinical Pharmacology, King's College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, UK christopher.floyd@kcl.ac.uk.
² Biomedical Research Centre, Clinical Research Facility, Guy's and St Thomas' NHS Foundation Trust, London, UK.

PMID: 31358525
DOI: 10.1136/dtb.2018.000060

No abstract available

Keywords: adverse effects; drug safety; hyperlipidaemia.

Publication types

Review

MeSH terms

Anticholesteremic Agents / administration & dosage
Anticholesteremic Agents / therapeutic use*
Clofibrate / administration & dosage
Clofibrate / therapeutic use*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Practice Patterns, Physicians'*
State Medicine
United Kingdom

Substances

Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Clofibrate